deltatrials
Completed PHASE1 INTERVENTIONAL NCT01222221

Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma

Sponsor: Cancer Research UK

Conditions Brain and Central Nervous System Tumors
Interventions adjuvant therapy glioblastoma multiforme multipeptide vaccine IMA950 laboratory biomarker analysis pharmacological study radiation therapy sargramostim temozolomide
Updated 6 times since 2017 Last updated: Oct 13, 2015 Started: Jul 31, 2010 Primary completion: Feb 28, 2015 Completion: Feb 28, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Brain and Central Nervous System Tumors and is currently completed. Cancer Research UK leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshotCompleted~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer Research UK
  • Immatics Biotechnologies GmbH
Data source: Cancer Research UK

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations